International Federation
of Pharmaceutical
Manufacturers & Associations

IFPMA

Current Initiatives of the Trade Associations: IFPMA

At 11th International Pharmaceutical and Medical Device Compliance Congress
Lisbon
17 May 2017

Sofie Melis
Senior Manager, Ethics & Compliance

The new CCN: eBIC
Ethics & Business Integrity

IFPMA

Name change reflects orientation from mere Code Compliance to broader ethical topics

New Chair since April 2017:
Melissa Stapleton Barnes
(Eli Lilly)

New Vice Chair since Dec 2016:
Holger Diener
(FSA)

eBIC Work Plan: Current issues

IFPMA

Charter / Guiding Principles
To create an overarching ethics and integrity framework

Promotion of Ethical Conduct for Member Organizations
To support and foster the highest ethical culture and business integrity standards within the IFPMA membership (companies and associations) to underline the global role of the IFPMA in this field

Medical Education	Gifts	Fees for Service	Outreach	Code Capacity Building
To address the legitimate role of Pharma Companies in terms of knowledge dissemination and scientific exchange, via Medical Education Programs, necessary to enhance medical practice and to ultimately improve patients care	Enhance the reputation and image of the industry by updating the current language on gifts & other items in the code, or by providing additional notes for guidance to clarify that any item, regardless of value, creates a potential conflict of interest	To ensure that payments made by member companies of the IFPMA to health professionals, healthcare organisations, patient organisations and others for service provision are appropriate. To ensure that stakeholders understand the need for the industry to work with these groups in the interests of improving patient care	**a) Stakeholder Interactions with IGOs:** Input and shape a stakeholder Outreach Campaign with regard to the main stake-holders such as WHO, UN and APEC, which is developed and sustained by the APEC Biopharmaceutical Ethics Initiative (initiative around industry ethical practices to improve reputation and perception of the pharmaceutical industry as well as to create a forum for positive communication around industry self-regulation activities)	To design and implement a structured Train-the-Trainer workshop in 2 key non-APEC emerging economies (LMICS) **b) Stakeholder Interactions with NGOs (e.g. TI, ATM):** Closely follow the several initiatives of different business ethics monitors to decide if and how the IFPMA can effectively reach out to these groups to promote the global role of the industry with regard to ethical standards and business integrity

So what about the Code?

Based on the outcome of the various working groups, the IFPMA Code of Practice, which is the global standard for the R&D biopharmaceutical industry, may be revised in some areas, other areas may just benefit from a Note for Guidance.

- Timeline: Mid-2018